These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 3872129)

  • 1. Patterns of antihistone antibody specificity in systemic rheumatic disease. I Systemic lupus erythematosus, mixed connective tissue disease, primary sicca syndrome, and rheumatoid arthritis with vasculitis.
    Bernstein RM; Hobbs RN; Lea DJ; Ward DJ; Hughes GR
    Arthritis Rheum; 1985 Mar; 28(3):285-93. PubMed ID: 3872129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of antibodies to histones, DNA and IgG in patients with systemic rheumatic diseases determined by ELISA.
    Gripenberg M; Helve T; Kurki P
    J Rheumatol; 1985 Oct; 12(5):934-9. PubMed ID: 3878880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of antinuclear anti-histone antibodies].
    Ferec C; Youinou P; Le Goff P; Miossec P; Morin JF; Pennec Y; Morin PP; Le Menn G
    Ann Med Interne (Paris); 1984; 135(6):427-30. PubMed ID: 6334466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.
    Tan EM
    Adv Immunol; 1982; 33():167-240. PubMed ID: 6182766
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA receptor dysfunction in systemic lupus erythematosus and kindred disorders. Induction by anti-DNA antibodies, antihistone antibodies, and antireceptor antibodies.
    Bennett RM; Kotzin BL; Merritt MJ
    J Exp Med; 1987 Oct; 166(4):850-63. PubMed ID: 2821153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihistone antibodies in systemic lupus erythematosus.
    Rubin RL; Waga S
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():118-26. PubMed ID: 2441043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on anti-histone fraction antibodies in patients with rheumatic diseases].
    Jiang M; He K; Yan CL
    Zhonghua Nei Ke Za Zhi; 1992 May; 31(5):287-9, 317-8. PubMed ID: 1478127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Specific antibodies of soluble nuclear antigens in autoimmune vasculitis].
    Weill BJ; Job-Deslandre C; Menkès CJ; Amor B
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):453-6. PubMed ID: 3303286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis.
    Ichikawa Y; Yamada C; Horiki T; Hoshina Y; Uchiyama M; Yamada Y; Toumatu J
    Clin Exp Rheumatol; 1998; 16(6):709-15. PubMed ID: 9844764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus.
    Amoura Z; Koutouzov S; Chabre H; Cacoub P; Amoura I; Musset L; Bach JF; Piette JC
    Arthritis Rheum; 2000 Jan; 43(1):76-84. PubMed ID: 10643702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Difficulties in differential diagnosis of Sjögren's syndrome and systemic lupus erythematosus].
    Krawiec P; Batko B; Skura A; Adamek-Guzik T; Cześnikiewicz-Guzik M; Krzanowski M; Rydz-Stryszowska I; Ryszawa N; Guzik TJ
    Przegl Lek; 2006; 63(5):278-83. PubMed ID: 17036505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-recognition between histones and La/SSB may account for anti-DNA reactivity in SLE patients.
    Touloupi E; Routsias JG; Tzioufas AG
    Clin Exp Immunol; 2005 Oct; 142(1):172-9. PubMed ID: 16178873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of antinuclear antibodies in systemic rheumatic diseases.
    Notman DD; Kurata N; Tan EM
    Ann Intern Med; 1975 Oct; 83(4):464-9. PubMed ID: 1080976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of antinuclear antibodies in the diagnosis of connective tissue diseases].
    Bambara LM; Biasi D; Caramaschi P; Codella O; Corrocher R; Serpelloni G; De Sandre G
    Recenti Prog Med; 1985 Feb; 76(2):102-9. PubMed ID: 3887516
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sharp's syndrome. Clinical, immunological and nosographic aspects].
    Scagliusi P; Muratore M; Martiradonna A; Berlingerio G; Carrozzo M
    Minerva Med; 1980 Dec; 71(50):3655-63. PubMed ID: 6161325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fluorimetric assay for human antibodies to all the histones.
    Hobbs RN; Lea DJ; Ward DJ
    J Immunol Methods; 1983 Dec; 65(1-2):235-43. PubMed ID: 6361141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease.
    Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T
    Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of anti-SSB antibodies in patients with rheumatic diseases.
    Tang F; Dong Y; Zhang N
    Chin Med Sci J; 1993 Mar; 8(1):55-8. PubMed ID: 8274726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies.
    Ghirardello A; Doria A; Zampieri S; Gerli R; Rapizzi E; Gambari PF
    Ann Rheum Dis; 2000 Dec; 59(12):975-81. PubMed ID: 11087701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.
    Merkel PA; Chang Y; Pierangeli SS; Convery K; Harris EN; Polisson RP
    Am J Med; 1996 Dec; 101(6):576-83. PubMed ID: 9003103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.